Localized targeted antiangiogenic drug delivery for glioblastoma
| Autor: | Abhiraj D. Bhimani, Tania M. Aguilar, Ankit I. Mehta, Gregory D. Arnone |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Angiogenesis medicine.medical_treatment Angiogenesis Inhibitors 03 medical and health sciences 0302 clinical medicine Drug Delivery Systems Internal medicine Glioma medicine Overall survival Animals Humans Chemotherapy business.industry Brain Neoplasms Recurrent glioblastoma Genetic Therapy medicine.disease Clinical trial Neurology 030220 oncology & carcinogenesis Neurology (clinical) business Glioblastoma Antiangiogenic drug 030217 neurology & neurosurgery |
| Zdroj: | Journal of neuro-oncology. 137(2) |
| ISSN: | 1573-7373 |
| Popis: | Systemic delivery of antiangiogenic agents has been ineffective in improving the overall survival of patients with both primary and recurrent glioblastoma, in part due to dose-limiting toxicities. With the development of new and efficient localized delivery methods and vehicles, an otherwise lethal dose of antiangiogenic chemotherapy can be used to treat tumors while minimizing systemic side effects. Current in-vitro and in-vivo animal studies have shown promising results that encourage the pursuit towards human clinical trials for localized antiangiogenic treatment in the near future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink